Bright Uro Highlights Market Need for Catheter-Free Urodynamics System

According to a recent LinkedIn post from Bright Uro, the company is drawing attention to high prevalence rates of urinary incontinence among adult women in the U.S., citing data that suggest tens of millions are affected and often remain undiagnosed. The post references urology experts who anticipate rising demand for care as awareness and need increase for a condition they describe as historically neglected.

The company’s LinkedIn post highlights its FDA-cleared Glean Urodynamics System, described as a wireless, catheter-free method for monitoring bladder function that aims to provide a more accurate and patient-centered diagnostic approach. For investors, the emphasis on a large, underserved patient population and a differentiated diagnostic technology suggests potential for market expansion in urodynamics and may position Bright Uro to capture demand as clinicians seek more patient-friendly solutions.